肿瘤抗原致敏树突状细胞疫苗治疗晚期恶性肿瘤的临床观察

被引：6

作者：

朱利明 ^{[1
]}

张沂平 ^{[1
]}

王晓稼 ^{[1
]}

钟海均 ^{[1
]}

范云 ^{[1
]}

余新民 ^{[1
]}

邓清华 ^{[2
]}

孔祥明 ^{[3
]}

应杰儿 ^{[1
]}

李铁 ^{[1
]}

娄广媛 ^{[1
]}

吴稚兵 ^{[3
]}

汤忠祝 ^{[2
]}

马胜林 ^{[2
]}

机构：

[1] 浙江省肿瘤医院化疗中心

[2] 浙江省肿瘤医院放疗科

[3] 浙江省肿瘤医院综合治疗科

来源：

中国肿瘤生物治疗杂志 | 2007年 / 06期

关键词：

树突状细胞; 疫苗; 恶性肿瘤; 免疫治疗; 不良反应; 临床试验;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 ;

摘要：

目的:观察肿瘤抗原致敏人树突状细胞(dendritic cell,DC)疫苗治疗各类晚期恶性肿瘤的不良反应,初步观察其治疗疗效。方法:91例非小细胞肺癌、结直肠癌、恶性黑素瘤、肾癌、乳腺癌等晚期恶性肿瘤患者入组,均符合试验的纳入组及排除标准,签署知情同意书,并报医院伦理委员会审查批准。患者单采外周血单核细胞体外培育成DC,用抗原致敏后制备成DC疫苗回输,每周回输1次,3次定义为1个周期。结果:91例患者共接受96个周期疫苗治疗;不良反应主要表现为寒战、发热、肌肉酸痛、皮肤瘙痒、胸闷及一过性全身无力,大部分为自限性;76例进行疗效评价,无完全缓解(complete remission,CR)及部分缓解(partial remission,PR)病例,治疗后稳定(stable disease,SD)31例,进展(progression disease,PD)45例,临床获益率40.8%;85例患者获得随访资料,患者中位达进展时间(median time to progression,mTTP)为2.6个月,生存时间为0.9～30.6个月,中位生存时间为4.5个月,1年生存率为9.2%。结论:肿瘤抗原致敏人DC疫苗治疗各类晚期恶性肿瘤耐受性良好,亦可见临床获益,疫苗临床应用方法有待进一步探讨。

引用

页码：567 / 570

页数：4

共 10 条

[1]

The use of dendritic cells in cancer immunotherapy. Schuler G,Schuler-Thurner B,Steinman RM. Current Opinion in Immunology . 2003

[2]

Placebo-con-trolled phaseⅢtrial of immunologic therapy with sipuleucel-T(APC8015)in patients with metastatic,asymptomatic hormonerefractory prostate cancer. Small EJ,Schellhammer PF,Higano CS,et al. Journal of Clinical Oncology . 2006

[3]

Dacarbazine(DTIC)versus vaccination with autologous peptide-pulsed den-dritic cells(DC)in first-line treatment of patients with metastaticmelanoma:a randomized phaseⅢtrial of the DC study group ofthe DeCOG. Schadendorf D,Ugurel S,Schuler-Thurner B,et al. Annals of Oncology . 2006

[4]

[5]

Active immunotherapy forcancer patients using tumor lysate pulsed dendritic cell vaccine:asafety study. Ovali E,Dikmen T,Sonmez M,et al. Journal of Experimental and Clinical Cancer Research . 2007

[6]

Intranodal administration of pep-tide-pulsed mature dendritic cell vaccines results in superiorCD8+T-cell function in melanoma patients. Bedrosian I,Mick R,Xu S,et al. Journal of Clinical Oncology . 2003

[7]

The dendritic cell system and its role in immunogenicity. Steinman RM. Annual Review of Immunology . 1991

[8]

Induction of strongand per-sistent MelanA/MART-1-specific i mmune responses by adjuvant den-dritic cell-based vaccination of stage II melanoma patients. Tuettenberg A,Becker C,Huter Eet al. Int J Canc-er . 2006

[9]

Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. Mullins DW,Sheasley SL,Ream RM,et al. The Journal of Experimental Medicine . 2003

[10]

Cellular immunotherapy with dendriticcells in cancer:current status. Nencioni A,Brossart P. Stem Cells . 2004

← 1 →